Sanofi
This is a real-world, mixed-methods observational study conducted among adolescent (ages 12-17 years) and adult participants diagnosed with hemophilia A or B, with or without Factor VIII (FVIII) or Factor IX (FIX) inhibitors, who are treated with fitusiran. The study includes a prospective longitudinal cohort (Cohort 1) and a cross-sectional cohort (Cohort 2). Data collection includes patient-reported outcomes via online surveys, qualitative interviews conducted via teleconference, and electronic medical record (EMR) review to describe real-world patient experiences, treatment satisfaction, adherence, and clinical management of fitusiran.
Inclusion Criteria: * Participant is English speaking * Participant is ≥ 12 years of age at the time of consent \-- Signed written informed consent by participants who are legally adults (i.e., have reached the age of majority as defined by local law) or legally authorized representative (e.g., parent) and assent (for participants under the age of majority by local law) * Participant has a diagnosis of hemophilia A or B * Participant is using fitusiran (QFITLIA) for: * Prospective cohort: \< 6 months at the time of consent * Cross-sectional cohort: 9-15 months at the time of consent *…
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.